KRON - Kronos: Recent IPO Developing Novel Oncology Therapies May, 25 2021 03:38 PM Kronos Bio Inc. Kronos IPO'd in October. Its lead asset Entospletinib is targeting a subset of AML patients. The company is well funded, with $398mn in cash. For further details see: Kronos: Recent IPO Developing Novel Oncology Therapies